ArticleAmerican journal of translational research2021
Anti-TNF therapy and immunogenicity in inflammatory bowel diseases: a translational approach.
Article in American journal of translational research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 19 citations in OpenAlex.
- rs2032582 polymorphism of ATP binding cassette subfamily B member 1 affect the susceptibility of inflammatory bowel disease: a systematical meta-analysis based on 14,876 subjects.International journal of colorectal disease · 2026Pooled it
- A systematic review and network meta-analysis of the association between periodontitis and inflammatory bowel diseases.BMC oral health · 2025Pooled it
- Special Issue: The Role of Cytokines in Disease.International journal of molecular sciences · 2026Article
- Intestinal taurine acts as a novel immunometabolic modulator of IBD by degrading redundant mitochondrial RNA.Cellular & molecular immunology · 2025Article
- Prevalence of Anti-Pathogens (Basel, Switzerland) · 2025Article
- TNF-α impairs platelet function by inhibiting autophagy and disrupting metabolism via syntaxin 17 downregulation.The Journal of clinical investigation · 2025Article
- Evaluating the potential hepatotoxicity from hip implant wear products-AnBiomaterials and biosystems · 2025Article
- Anti-Inflammatory Effects of Algae-Derived Biomolecules in Gut Health: A Review.International journal of molecular sciences · 2025Review
- The Multiple Roles of Heat Shock Proteins in the Development of Inflammatory Bowel Disease.Current molecular medicine · 2025Review
- The Effect of Biologic Agents on Steatotic Liver Disease in Patients with Inflammatory Bowel Disease: A Prospective, Open-Label Comparative Trial.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Interferon-gamma signaling drives epithelial TNF-alpha receptor-2 expression during colonic tissue repair.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2024Article
- Cystathionine Gamma-Lyase Regulates TNF-α-Mediated Injury Response in Human Colonic Epithelial Cells and Colonoids.Antioxidants (Basel, Switzerland) · 2024Article
- Engineering a Novel Probiotic Toolkit inACS synthetic biology · 2024Article
- The role of IL-37 in gastrointestinal diseases.Frontiers in immunology · 2024Review
- Article
- The continuing value of mesalazine as first-line therapy for patients with moderately active ulcerative colitis.Frontiers in gastroenterology (Lausanne, Switzerland) · 2024Article
- Imaging Agents for PET of Inflammatory Bowel Disease: A Review.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023Review
- Therapeutic drug monitoring and immunogenetic factors associated with the use of adalimumab in Crohn's disease patients.International journal of immunopathology and pharmacologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel diseases are chronic illnesses that involve intestinal inflammation and are usually diagnosed as Crohn's disease or ulcerative colitis. As these diseases do not have a cure, the goal of treatment is to induce and maintain remission. Monoclonal antibodies have been recognized as the most advanced therapy to avoid complications and reduce the need for surgical approaches. However, although their effectiveness has been proven by several studies, they can trigger the immune system, induce the occurrence of immunogenicity, which may lead to the loss of response and treatment failure. The purpose of this review is to determine what are the main mechanisms involved in IBD; to assess the recommended treatments; to explore the mechanisms of immunogenicity. We also try to explain the detection and describe the existing advances that make possible the clinical application of these approaches.
Indexed as
Identifiers
35035733PMC8748125W4206882968What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.